NEW YORK (GenomeWeb News) - Shares in Orchid Cellmark were up approximately 16 percent, or $.33, at $2.45 in mid-afternoon trading today despite the company’s 14-percent decline in revenues and second-quarter loss.
As GenomeWeb News reported this morning, Orchid today posted a 14-percent decline in revenues amid mounting losses for the second quarter.